The FDA has signed off on ProQR Therapeutics’ (PRQR -0.1%) IND for a Phase 1/2 clinical trial evaluating QR-1123 for the treatment of vision loss associated with autosomal-dominant retinitis pigmentosa (adRP) due to a mutation in the RHO gene called P23H, the most common mutation related to adRP in the U.S. Enrollment (up to 12 subjects) should start later this year.
The company in-licensed the antisense oligonucleotide from Ionis Pharmaceuticals (IONS -0.1%) in October 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.